

## ViroGates Equity Story

ViroGates is an in-vitro diagnostic company focused on improving patient outcomes through developing and commercializing novel diagnostic tests. With a strong track record of innovation, the company has developed a unique technology platform that enables rapid and reliable measurement of its biomarker-product suPARnostic® in blood samples.

ViroGates is well-positioned to capture a significant share of the rapidly growing market for diagnostic tests, driven by the increasing demand for personalized and precision medicine. The company's flagship product, suPARnostic®, is a groundbreaking test that measures the level of suPAR, a protein biomarker associated with inflammation and disease severity, in patient blood samples. This test has demonstrated significant clinical utility in various diseases, including COVID-19, sepsis, cardiovascular disease etc.

ViroGates has a robust intellectual property portfolio, including multiple patents on its use cases. The company has also established strategic partnerships with leading healthcare organizations, including hospitals, academic institutions, and research centers, to further develop and validate its diagnostic tests.

With a highly experienced management team and a dedicated workforce, ViroGates is well-equipped to execute its growth strategy and capitalize on the significant market opportunity. The company is committed to expanding its product portfolio and commercializing its diagnostic tests globally, with a focus on high-growth markets in Europe and, subsequently, North America and Asia.

Investing in ViroGates offers the opportunity to participate in the growth of a cutting-edge in-vitro diagnostic company with a strong value proposition and significant market potential.




## ViroGates Shares

ViroGates' shares (VIRO) have been listed on Nasdaq First North Growth Market Denmark since 2018.



Share Data	07/05/2024
Previous Close	6.84
Change (%)	-4.20
Volume	87
Number of Shares	6,447,554
Market Cap	44.10

KEY FIGURES – DKK ('000)	2023	2022
<b>Income statement</b>		
Net revenue	5,582	10,151
Operating profit/loss	-12,565	-10,845
Profit/loss for the year	-12,096	-9,646
<b>Balance sheet</b>		
Balance sheet total	24,555	17,539
Equity	17,007	16,088
Invested capital	6,909	6,898
<b>Cash flows</b>		
Cash flows from operating activities	-12,179	-14,276
Cash flows from investment related activities	12	-13
Cash flows from financing activities	18,315	9,308
Total cash flows	6,149	-4,981
Cash and cash equivalents	16,027	9,878
<b>Ratios</b>		
Rate of return	-182	-185.2
Number of employees, end of period	10	9
Market share price, end of period (DKK)	6.02	40.1



Sales by product (2022)



- 45% Turbilatex
- 8% Quick Triage
- 45% ELISA
- 1% Other\*

\* Other includes analysis services, freight and handling

## MAJOR SHAREHOLDERS

At the end of 2023, ViroGates had 1,627 registered shareholders. Four shareholders had notified shareholdings of 5% or more:

Shareholders (31/12/2023)	Number Of Shares	Percent Of Capital
N. P. Louis-Hansen ApS	1,598,150	24.79%
Ginnerup Capital ApS	685,330	10.63%
4AM ApS	685,264	10.63%
Aetas Healthcare ApS	383,941	5.95%

## ViroGates A/S

Banevænget 13  
DK-3460 Birkerød  
Denmark

